



MannKind Corporation
Investor Relations Department
25134 Rye Canyon Loop
Suite 300
Valencia, CA 91355
United States

[Visit IR website](#)

[Sign-up for e-mail alerts](#)

NASDAQ and TASE: MNKD ¹

| | |
|-------------------|--|
| Last Trade: | 4.11 |
| Trade Time: | 4:00 PM ET 10/20/17 |
| Change: | 0.15 ↑ (3.788%) |
| Day Range | 3.87 - 4.45 |
| 52-Week Range | 0.67 - 6.96 |
| Volume | 11,426,135 |
| Market Cap. (\$M) | 472.116 |
| Shares Out (M) | 114.870 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

MannKind Corporation (Nasdaq and TASE: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh), approved in 2014 by the U.S. Food and Drug Administration is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.

AFREZZA utilizes our proprietary Technosphere® formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be

Stock Performance



Press Releases [\[View all \]](#)

10/12/17
[MannKind Donates Afrezza® to Support People with Diabetes Impacted by Hurricane Maria in Puerto Rico](#)

10/11/17
[MannKind Announces \\$61 Million Registered Direct Offering of Common Stock](#)

10/02/17
[FDA Updates Afrezza® Prescribing Information](#)

10/01/17
[MannKind Corporation to Hold Investor Conference Call](#)

09/07/17
[MannKind Responds to Hurricane Harvey Devastation with Afrezza® Donation](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

03/16/17
[Annual Report \(10-K\)](#)

04/07/17
[Definitive Proxy Statement](#)

08/07/17
[Quarterly Report \(10-Q\)](#)

05/10/17
[Quarterly Report \(10-Q\)](#)

11/09/16
[Quarterly Report \(10-Q\)](#)

loaded. We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

... [\(more\)](#)